Edition:
United States

Vitrolife AB (VITR.ST)

VITR.ST on Stockholm Stock Exchange

505.00SEK
11:29am EDT
Change (% chg)

-5.00kr (-0.98%)
Prev Close
510.00kr
Open
515.00kr
Day's High
517.00kr
Day's Low
494.00kr
Volume
13,980
Avg. Vol
24,837
52-wk High
559.00kr
52-wk Low
350.00kr

Latest Key Developments (Source: Significant Developments)

Vitrolife Q1 EBITDA rises 53 pct yr/yr
Tuesday, 25 Apr 2017 02:30am EDT 

April 25 (Reuters) - Vitrolife AB :Q1 sales amounted to SEK 244 (187) million.Q1 operating income before depreciation and amortisation (EBITDA) amounted to SEK 95 (62) million.Q1 net sales growth was 27 percent in local currency.Looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife Q4 core profit rose to SEK 96 mln
Thursday, 9 Feb 2017 02:30am EST 

Vitrolife Ab : Q4 sales amounted to SEK 251 (199) million, corresponding to an increase of 26 percent in SEK. Net sales growth was 21 percent in local currency. . Q4 operating income before depreciation and amortisation (ebitda) amounted to SEK 96 (81) million . Q4 board proposes a dividend of SEK 2.60 (2.40) per share. .Says looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future..  Full Article

Vitrolife Q3 EBITDA profit narrows to SEK 71 mln
Thursday, 3 Nov 2016 03:30am EDT 

Vitrolife AB : Q3 sales amounted to SEK 210 (177) million .Q3 operating income before depreciation and amortisation (EBITDA) amounted to SEK 71 (82) million.  Full Article

Vitrolife Q2 core profit rises, market outlook unchanged
Friday, 15 Jul 2016 02:30am EDT 

Vitrolife AB : Q2 sales amounted to sek 208 (184) million . Q2 operating income before depreciation and amortisation (ebitda) amounted to sek 74 (62) million, corresponding to a margin of 35 (34) percent. .Says market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife says buys OCTAX and MTG
Wednesday, 1 Jun 2016 02:37am EDT 

Vitrolife Ab : Vitrolife acquiring octax and mtg, jointly holding a world-leading position in laser technology for IVF . Vitrolife AB (publ) has completed the acquisition of 100% of the shares in OCTAX Microscience GmbH "OCTAX" and MTG Medical Technology Vertriebs-GmbH "MTG" . The consolidated net sales for the companies in 2015 amounted to approximately EUR 8.5 million (6.9) . The purchase sum for both companies amounted to EUR 13.7 million . The acquisitions are expected to be accretive to earnings per share from 2016 and onwards Further company coverage: [VITR.ST].  Full Article

Vitrolife proposes FY 2015 dividend of SEK2.40/shr
Friday, 5 Feb 2016 02:30am EST 

Vitrolife AB:Says ‍board proposes a FY 2015 dividend of 2.40 Swedish crowns per share.  Full Article

William Demant raises Vitrolife stake to 17.7 pct
Wednesday, 9 Dec 2015 06:38am EST 

Finansinspektionen:‍William Demant Invest A/S raises holding to 3,851,210 shares in Vitrolife AB, corresponding to 17.7 percent.  Full Article

More From Around the Web

BRIEF-Vitrolife Q1 EBITDA rises 53 pct yr/yr

* Q1 operating income before depreciation and amortisation (EBITDA) amounted to SEK 95 (62) million